A Study of ANAVEX3-71 in Adults With Schizophrenia - Trial NCT06245213
Access comprehensive clinical trial information for NCT06245213 through Pure Global AI's free database. This Phase 2 trial is sponsored by Anavex Life Sciences Corp. and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Anavex Life Sciences Corp.
Timeline & Enrollment
Phase 2
Mar 15, 2024
May 15, 2025
Primary Outcome
Single Dose Maximum Observed Plasma Concentration (Cmax),Multiple Dose Maximum Observed Plasma Concentration (Cmax),Cmax (steady state),Tmax (steady state),AUC (steady state),AUC (single state),CL/F (steady state),Vz/F (steady state),T1/2 (steady state),Rac (steady state),Rac, Cmax (steady state),PTR (steady state),Adverse Events,Vital Signs,12-lead ECG (RR interval),12-lead ECG (P wave),12-lead ECG (PR interval),12-lead ECG (PR segment),12-lead ECG (QRS complex),12-lead ECG (ST segment),12-lead ECG (T wave),12-lead ECG (QT interval),Clinical Safety Labs - Renal Panel,Clinical Safety Labs - Hepatic Panel,Clinical Safety Labs - Lipid Panel,Clinical Safety Labs - Hematology Panel,Clinical Safety Labs - Urinalysis Panel,Clinical Safety Labs - Coagulation Panel,Brief Physical Examination,Brief Neurological Examination,AIMS,SAS,BARS,CDSS,C-SSRS,EEG-ERP - Passive, Duration Deviant, Oddball ERP,EEG-ERP - Active, Auditory, Oddball ERP,EEG-ERP - Auditory Steady State Response,EEG-ERP - Resting EEG
Summary
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and
 electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06245213
Non-Device Trial